Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 3
2023 6
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean beolchini m (9 results)?
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study).
Iannone LF, Vaghi G, Sebastianelli G, Casillo F, Russo A, Silvestro M, Pistoia F, Volta GD, Cortinovis M, Chiarugi A, Montisano DA, Prudenzano MP, Cevoli S, Mampreso E, Avino G, Romozzi M, Valente M, Fasano C, Battistini S, Granato A, Piella EM, Rainero I, Ornello R, De Icco R; Italian Headache Registry (RICe) Study Group. Iannone LF, et al. J Headache Pain. 2025 Jan 6;26(1):4. doi: 10.1186/s10194-024-01935-8. J Headache Pain. 2025. PMID: 39762740 Free PMC article.
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.
Schiano di Cola F, Caratozzolo S, Bolchini M, Ceccardi G, Cortinovis M, Liberini P, Padovani A, Rao R. Schiano di Cola F, et al. Among authors: bolchini m. Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26. Neurol Sci. 2022. PMID: 35618933 Free PMC article. No abstract available.
Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study.
Iannone LF, Romozzi M, Russo A, Saporito G, De Santis F, Ornello R, Sances G, Vaghi G, Tassorelli C, Albanese M, Guerzoni S, Casalena A, Vollono C, Calabresi P, Prudenzano MP, Mampreso E, Volta GD, Valente MR, Avino G, Chiarugi A, Sacco S, Pistoia F; Italian Headache Registry (RICe) study group. Iannone LF, et al. Eur J Neurol. 2024 Dec;31(12):e16450. doi: 10.1111/ene.16450. Epub 2024 Sep 16. Eur J Neurol. 2024. PMID: 39285638 Free PMC article.
Photophobia and migraine outcome during treatment with galcanezumab.
Schiano di Cola F, Ceccardi G, Bolchini M, Caratozzolo S, Liberini P, Padovani A, Rao R. Schiano di Cola F, et al. Among authors: bolchini m. Front Neurol. 2023 Jan 18;13:1088036. doi: 10.3389/fneur.2022.1088036. eCollection 2022. Front Neurol. 2023. PMID: 36742057 Free PMC article.
14 results